Cipla Limited

https://www.cipla.com/home

Already a Biomedtracker subscriber? You have access to the full company record through your subscription

Want to become a subscriber? Subscribers get more company details, updates, company financials and company products.

Questions?

Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com

COVID-19 Relapses, Lack Of Omicron Data Complicate Paxlovid Case In India

Bookmark

13 May 2022
Analysis

By Vibha Ravi

A few cases of COVID-19 relapse have Twitter abuzz about the need for data on Paxlovid’s effectiveness, particularly against the Omicron variant and in vaccinated individuals. Despite regulatory approval in India, the drug has not yet been included in treatment guidelines and a debate on recommended dosage now complicates matters

Commercial Coronavirus COVID-19

Will Yabao Help Lupin’s Attempts To Scale The Great Wall?

Bookmark

09 May 2022
Analysis

By Vibha Ravi and Brian Yang

With the Yabao partnership, Lupin builds on a toehold gained through the Foncoo tie-up as it attempts to scale the market behind the Great Wall of China. Scrip takes a look at possible approaches and potential of the partnership

Commercial Business Strategies

Shilpa Medicare’s Plan For Eylea Biosimilar Spells Ambition, But Path Not Easy

Bookmark

02 May 2022
Analysis

By Vibha Ravi

Shilpa Medicare’s plan for trials of an Eylea biosimilar shows the company’s ambition to leapfrog to a biosimilars-led growth strategy, one that Indian majors like Cipla and Lupin pivoted to post a successful generics program. However, the path isn’t going to be easy and Biocon/Viatris, Samsung Biologics are ahead

Research & Development Biosimilars